pityriasis%20(tinea)%20versicolor
PITYRIASIS (TINEA) VERSICOLOR
Pityriasis (Tinea) versicolor is a fungal infection caused by Malassezia furfur. It is benign, superficial, and localized to the stratum corneum.
It may present as chronic or recurrent infection and may occur in healthy individuals.
It is more common in summer than winter months.
It presents with multiple well-demarcated macules or patches and finely scaled plaques with hypopigmentation or hyperpigmentation, hence the term "versicolor".
Lesions are usually found on the upper trunk, chest, back and shoulders, and may extend toward the neck, face and arms.
Drug Information

Indication: Cryptococcosis. Systemic, mucosal & vag candidiasis. Prevention of fungal infection in patient w/ malignan...

Indication: Topical treatment of the tinea pedis, tinea cruris, tinea corporis, tinea versicolor, erythrasma candidiasis d...

Indication: Ear drops: Otomycosis. Prophylaxis for swimmers. Lotion: Tinea capitis, tinea barbae, tinea unguium, tinea cor...

Indication: Dermatomycoses, Candida vulvitis & Candida balanitis, pityriasis versicolor, erythrasma.

Indication: Topical fungal infection caused by dermatophytes, yeast, moulds & other fungi including Tinea infections, ...

Indication: Fungal skin infections due to dermatophytes & other dermal infections eg, Tinea pedis, cruris & corpor...

Indication: Topical fungal infection caused by dermatophytes, yeast infection, pityriasis versicolour & cutaneous cand...

Indication: Tinea pedia, tinea cruris & tinea corporis, cutaneous candidiasis & tinea versicolor.

Indication: Topical treatment of tinea corporis, tinea cruris, tinea pedis, pityriasis versicolor & cutaneous candidiasis.

Dezor Plus
ketoconazole + zinc pyrithione

Indication: Topical treatment of seborrheic scalp dermatitis & dandruff.

2  /  9
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Infectious Diseases - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 4 days ago
Every-two-month injections of the long-acting cabotegravir + rilpivirine were noninferior to once-monthly injections for virologic suppression at 48 weeks in people living with HIV*, according to the ATLAS-2M** study presented at CROI 2020 — thus providing a potential option with more convenient dosing.
Stephen Padilla, 19 Mar 2020
The assumption that children are less vulnerable to the coronavirus disease 2019 (COVID-19) compared to adults is not quite true and may even be dangerous, suggests a recent study.
22 Mar 2020
Sustained use of lopinavir-combined regimen appears to confer benefits among patients with the novel coronavirus disease (COVID-19), with improvement possibly indicated by increasing eosinophils, suggests a recent study.
24 Mar 2020
COVID-19 is a novel disease, with no existing immunity. The virus can be transmitted from person to person, quickly and exponentially. Here’s what we can do to slow down the spread, if not contain the outbreak.